Induction of bulk and c-myc P2 promoter-specific DNA damage by an anti-topoisomerase II agent salvicine is an early event leading to apoptosis in HL-60 cells

被引:17
作者
Meng, LH [1 ]
Ding, J [1 ]
机构
[1] Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai Inst Mat Med, State Key Lab Drug Res,Div Antitumor Pharmacol, Shanghai 200031, Peoples R China
基金
中国国家自然科学基金;
关键词
salvicine; P2; promoter; DNA damage; c-myc; DNA topoisomerase II inhibitor;
D O I
10.1016/S0014-5793(01)02633-3
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Salvicine is a novel diterpenoid quinone derivative possessing strong antitumor activities and was demonstrated to stabilize the DNA topoisomerase II (Topo II) cleavage complex in vitro and in vivo. In the present work we investigated the possible mechanism through which disturbance of Topo II by salvicine led to cell death. We found that salvicine induced DNA strand breaks in human promyelocytic leukemia HL-60 cells and DNA damage correlated with cell growth inhibition. DNA damage induced by brief exposure to salvicine could be partially reversed, but early DNA breaks triggered the process of apoptosis, Preferential damage in the P2 promoter region of the oncogene c-myc was detected, whereas no obvious DNA damage was found in the 3 ' region of the same gene, Furthermore, the expression of some protooncogenes such as c-myc, c-fos and c-jun was examined, showing that salvicine produced a reduction in the transcription rate of c-myc in a dose-dependent manner and a marked induction of c-fos and c-jun expression was observed. It appears possible that DNA damage within such genomic regions is an early event, which could lead to growth inhibition mediated by alterations of the expression of selected proliferation regulatory genes, such as c-myc, c-fos and c-jun, and ultimately cell death. (C) 2001 Published by Elsevier Science B.V. on behalf of the Federation of European Biochemical Societies.
引用
收藏
页码:59 / 64
页数:6
相关论文
共 32 条
[1]  
BERTRAND R, 1991, CANCER RES, V51, P6280
[2]   INFLUENCE OF AMSACRINE (M-AMSA) ON BULK AND GENE-SPECIFIC DNA-DAMAGE AND C-MYC EXPRESSION IN MCF-7 BREAST-TUMOR CELLS [J].
BUNCH, RT ;
POVIRK, LF ;
ORR, MS ;
RANDOLPH, JK ;
FORNARI, FA ;
GEWIRTZ, DA .
BIOCHEMICAL PHARMACOLOGY, 1994, 47 (02) :317-329
[3]  
CARMICHAEL J, 1987, CANCER RES, V47, P943
[4]   Inhibition of gene expression and cell proliferation by triple helix-forming oligonucleotides directed to the c-myc gene [J].
Catapano, CV ;
McGuffie, EM ;
Pacheco, D ;
Carbone, GMR .
BIOCHEMISTRY, 2000, 39 (17) :5126-5138
[5]  
CLARK HL, 1898, MEM BOST SOC NAT HIS, V5, P53
[6]  
COVEY JM, 1988, CANCER RES, V48, P860
[7]   DNA TOPOISOMERASE-II CLEAVES AT SPECIFIC SITES IN THE 5' FLANKING REGION OF C-FOS PROTOONCOGENES INVITRO [J].
DARBY, MK ;
HERRERA, RE ;
VOSBERG, HP ;
NORDHEIM, A .
EMBO JOURNAL, 1986, 5 (09) :2257-2265
[8]  
DAVIES SM, 1988, J BIOL CHEM, V263, P17724
[9]   DOES BULK DAMAGE TO DNA EXPLAIN THE CYTOSTATIC AND CYTOTOXIC EFFECTS OF TOPOISOMERASE-II INHIBITORS [J].
GEWIRTZ, DA .
BIOCHEMICAL PHARMACOLOGY, 1991, 42 (12) :2253-2258
[10]   Induction of DNA damage, inhibition of DNA synthesis and suppression of c-myc expression by the anthracycline analog, idarubicin (4-demethoxy-daunorubicin) in the MCF-7 breast tumor cell line [J].
Gewirtz, DA ;
Randolph, JK ;
Chawla, J ;
Orr, MS ;
Fornari, FA .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1998, 41 (05) :361-369